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Piperidone heterocycle have gained a considerable attention in the field of drug discovery. The wide range of its therapeutic 
application paved the way to the researchers to insert the nucleus every now and then in diversified pharmacophore, so as to generate 
novel therapeutic profile. In this review, we have tried to present various therapeutic applications, which have already been 
demystified by the researchers. The study may prompt the researcher to generate scaffolds of highest therapeutic efficacy 
considering the importance of 4- Piperidone nucleus. 
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INTRODUCTION 
4-piperidone is a monocyclic compound with the molecular 
formula C5H9 NO. This heterocyclic amine consists of six 
member ring containing five methylene units and one nitrogen 
atom in adjacent position, at no 4th position carbonyl group 
present and to the unsubstituted parent compound. 
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Properties 
Molecular formula: C5H9 NO 
Molar Mass: 99.13106 gm/mol 
 
Many substituted piperidone derivatives are acknowledged to 
possess a wide range of bioactivities as antiviral, antitumor, 
anti inflammatory, central nervous system depressant, local 
anaesthetic, anticancer, antidiabetic and antimicrobials. In the 
foregoing section, we preferentially wanted to shape our study 
in a manner of target oriented development of piperidones 
 
PIPERIDINE MOIETY AS ANTI MICROBIAL AGENTS: 
Aridoss8 et al designed, synthesized and evaluated a series of 
imidazo (4, 5- b) pyridinyl     ethoxy piperidones derivatives, 
which showed good inhibitory activity against bacterial as well 
as fungal strains.  
Among the two derivatives 1b exerted strong in vitro 
antibacterial activity against Bacillus subtilis and 
Staphylococcus aureus whereas, compounds 1a and 1b 
displayed promising antifungal activity against Aspergillus  
flavus. 
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1a     1b 
Aridoss8 et al synthesized an array of novel N-
morpholinoacetyl-2, 6-diarylpiperidin-4-ones (2) and evaluated 
there in vitro antibacterial and antifungal activity.  
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Among the four derivatives the compounds c and d exerted 
excellent antibacterial activity against all the bacterial strains 
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used except d against S. aureus. against C. Albicans and A. 
flavus, compound a recorded excellent antifungal activities, 
compound b showed potent activities.  
Das9 et al designed, synthesized & evaluated the cytotoxic 
properties of some 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-
3,5-bis(arylidene)-4-piperidones(3,4,5) and related compounds 
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Compounds 3a, b; 4a; 5a-m were more potent than melphalan. 
A comparison of the potencies between the compounds in 
series 3 and the related nonquaternary analogues of series 4 and 
5 revealed that in approximately half of the comparisons made, 
compounds of 4 and 5 series had increased potencies.  
Jha19 et al synthesized a series of E, E, E-3, 5-bis (arylidene)-1-
(4-arylamino-4-oxo-2-butenoyl)-4-piperidones (6) in order to 
explore the structural features of the N-acyl group which 
affects the cytotoxic potency. 
The raise in clinical significance of multidrug-resistant 
bacterial pathogens has directed, Aridoss16 et al to synthesize 2, 
6-diarylpiperidin-4-one and tetrahydropyridin-4-ol based 
benzimidazole and O-arylsulfonyl derivatives (7, 8).  
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Antibacterial activities have been evaluated against a wide 
range of bacterial pathogens (both sensitive and multidrug-
resistant) revealed that 7a, 8c against Staphylococcus aureus, 
8c against Enterococcus faecalis, and 7a, 7b, 8a, and 8c against 
Enterococcus faecium are significantly good at lowest MIC (16 
µg/ml). Inhibitory power noticed by 8a against Vancomycin–
Linezolid- resistant E. faecalis and 8c against Vancomycin-
resistant E. faecium are onefold better than the standard 
Linezolid and Trovafloxacin drugs, respectively. Moreover, 
antitubercular activity for the selected compounds against 
Mycobacterium tuberculosis H37Rv revealed that compounds 
8a, b, c expressed one fold improved potency compared to the 
standard Rifampicin drug. 
Inhibitory power noticed by 8a against Vancomycin–Linezolid- 
resistant E. faecalis and 8c against Vancomycin-resistant E. 
faecium are onefold better than the standard Linezolid and 
Trovafloxacin drugs, respectively. Moreover, antitubercular 
activity for the selected compounds against Mycobacterium 
tuberculosis H37Rv revealed that compounds 8a, b, c 
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expressed onefold improved potency compared to the standard 
Rifampicin drug. 
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Das18 et al synthesized a number of 3, 5-bis (benzylidene)-4-
piperidones and some N-4-(2-aminoethoxy) phenylcarbonyl 
analogs (9) which display excellent in vitro antimycobacterial 
properties. In particular, 9a and 9b are potent 
antimycobacterials which are well tolerated in mice and are 
identified as important lead molecules. The nature of both the 
benzylidene aryl rings and the terminal basic groups which 
affect the antimycobacterial potencies and the absence of 
neurotoxic side effects were identified.  
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Aridoss17 et al have a stereo specifically synthesized a series of 
thiazolidiones and thiazoles based on 3-alkyl-2, 6-
diarylpiperidin-4-ones. 
Compounds 10a, b, d, f, g and h exhibited twofold enhanced 
potency than Rifampicin, a antimycobacterial as well as, 
compounds 10c and 10e have exceptionally promising 
antimicrobial activities and particularly, 10c against 
Staphylococcus aureus and, 10d and 10h against Rhizopus sp. 
exhibited one fold elevated inhibition potency whereas 10c 
against Klebsiella pneumoniae showed twofold improved 
potency than Ciprofloxacin and Amphotericin B. 
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Parthiban20 et al synthesized three series of oxime ethers viz, 2, 
6-diarylpiperidin-4-one O-benzyloximes, 2, 6-
diaryltetrahydropyran- 4-one O-benzyloximes and 2, 6-
diaryltetrahydrothiopyran-4-one O-benzyloximes (11) and 
stereochemistry were established by their spectral and single 
crystal analysis. A SAR study had carried out for the above 
oxime ethers against a panel of antibacterial and antifungal 
agents respectively, using Ciprofloxacin and Amphotericin B 
as standards.    
Most of the chloro/methyl/ methoxy substituted compounds 
exerted moderate to good activity against all the tested 
organisms; moreover, some compounds 11(a, b, c, d, e, f, g, h 
and i) exhibited promising activity than standard drugs. 
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CONCLUSION 
The above studies clearly mention the potentiality of 
piperidone moiety accompanied with other molecular 
fragments in ameliorating various disease conditions. Owing to 
its accessibility to various important biogenic residues, it has 
been included in many xenobiotics. The synthetic feasibility 
and suitable insertion into many other structural frameworks 
will surely prompt the researchers to synthesise a huge number 
of compounds considering piperidone as an effective scaffold, 
which may demystify various unexplored pathogenic target. 
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